UBS Downgrades ResMed to Neutral, Raises Price Target to $174

UBS analyst Saul Hadassin downgrades ResMed (NYSE:RMD) from Buy to Neutral and raises the price target from $150 to $174.

Benzinga · 01/31/2020 12:16

UBS analyst Saul Hadassin downgrades ResMed (NYSE:RMD) from Buy to Neutral and raises the price target from $150 to $174.